DiaMedica Therapeutics Inc. (DMAC) Operating income 2017–2025
DiaMedica Therapeutics Inc. (DMAC) annual operating income history from SEC filings — each fiscal year as reported.
-$34.4MFY2025 · since FY2017: -$4.5M → -$34.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$34.4M | -28.9% |
| FY2024 | -$26.7M | -25.5% |
| FY2023 | -$21.3M | -51.9% |
| FY2022 | -$14.0M | -2.6% |
| FY2021 | -$13.6M | -7.5% |
| FY2020 | -$12.7M | -9.5% |
| FY2019 | -$11.6M | -71.5% |
| FY2018 | -$6.8M | -49.6% |
| FY2017 | -$4.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DMAC financial trends
DMAC RevenueDMAC Net incomeDMAC Net marginDMAC Gross profitDMAC Gross marginDMAC Operating marginDMAC Operating cash flowDMAC Free cash flowDMAC Capital expendituresDMAC Return on equityDMAC Stock buybacksDMAC Dividends paidDMAC Total assetsDMAC Total liabilitiesDMAC Shareholders’ equityDMAC overview →